Core One Labs Balans Gezondheid

Financiële gezondheid criteriumcontroles 0/6

Onvoldoende gegevens om de gezondheid van Core One Labs te bepalen

Belangrijke informatie

n/a

Verhouding schuld/eigen vermogen

n/a

Schuld

Rente dekkingsratio	n/a
Contant	n/a
Aandelen	n/a
Totaal verplichtingen	n/a
Totaal activa	n/a

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: Er zijn onvoldoende gegevens om te bepalen of de kortetermijnactiva van LD6 de kortetermijnschulden dekken.

Langlopende schulden: Er zijn onvoldoende gegevens om te bepalen of de kortetermijnactiva van LD6 de langetermijnschulden dekken.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: Er zijn onvoldoende gegevens om de netto schuld/eigen vermogen ratio LD6 te berekenen om te bepalen of deze voldoende is.

Schuld verminderen: Er zijn onvoldoende gegevens om te bepalen of de schuld/eigen vermogen-ratio van LD6 de afgelopen 5 jaar is gedaald.

Schuldendekking: Er zijn onvoldoende gegevens om te bepalen of de schulden van LD6 goed gedekt zijn door de operationele kasstroom.

Rentedekking: Er zijn onvoldoende gegevens om te bepalen of de rentebetalingen van LD6 op haar schulden goed worden gedekt door EBIT.

Core One Labs Balans Gezondheid

Financiële gezondheid criteriumcontroles 0/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

New major risk - Financial data availability

Core One Labs Inc. announced that it expects to receive CAD 1.5 million in funding

New minor risk - Financial data availability

Core One Labs' Akome Reveals Impressive Results for Its Psychedelic Bio- Compounds Designed to Target Alzheimer's and Parkinson's, Showing Potential to Outperform Current Treatment Methods

New major risk - Market cap size

New major risk - Shareholder dilution

Core One Labs Inc. announced that it has received CAD 0.2 million in funding

Core One Labs Inc. announced that it has received CAD 0.2 million in funding

Core One Labs Inc. announced that it expects to receive CAD 1 million in funding

Core One Labs Inc. announced that it expects to receive CAD 1 million in funding

Core One's Akome Reveals Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's Disease

Full year 2023 earnings released: CA$0.49 loss per share (vs CA$1.40 loss in FY 2022)

Core One Labs Inc.'s Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease

Core One Labs Inc. Announces Management Changes

Core One Labs Inc. (CNSX:COOL) acquired GMP Drug Inc. for CAD 3.5 million.

Core One Labs Inc., Annual General Meeting, Feb 08, 2023

Core One Labs Inc. Prepares for Commercial Production of API-Grade Psilocybin

Less than half of directors are independent

Core One Labs Applauds New Study Supporting Psilocybin Psychedelic Drug Therapy May Help Treat Alcohol Addiction

Core One Labs Inc. Announces Resignation of Ryan Hoggan from its Board of Directors

Less than half of directors are independent

Core One Labs Inc. (CNSX:COOL) acquired Awakened Biosciences Inc.

Core One Labs Inc. Expects Imminent Breakthrough to Produce NMT, Precursor to DMT

Core One Labs Applauds Health Canada’s Amendments to Special Access Program, Allowing Physicians to Request Patient Access to Psychedelic Treatments

Core One Labs Inc. (CNSX:COOL) acquired New Path Laboratories Inc. for CAD 3.4 million.

Core One Labs Inc. (CNSX:COOL) acquired Frontier Mycology Corp. for CAD 7.5 million.

Executive Chairman recently sold €55k worth of stock

Chief Science Officer & Director John Sanderson has left the company

Core One Labs Inc. (CNSX:COOL) completed the acquisition of Akome Biotech Ltd.

Core One Labs Inc. (CNSX:COOL) acquired Bluejay Mental Health Group Inc.

Core One Labs in Collaboration with KICT to Explore DMT Assisted Psychotherapy

Core One Labs Inc. and Vocan Biotechnologies Inc. Initiates First Strain Production for Biosynthetic Psilocybin

Executive Chairman recently sold €65k worth of stock

Core One Labs Inc. (CNSX:COOL) entered into a letter of intent to acquire Ketamine Infusion Centers of Texas, LLC for $0.2 million.

High Tower Capital, Inc. completed the acquisition of Certain Assets of Core One Labs Inc. (CNSX : COOL).

Core One Labs Announces Breakthrough in Solving Psilocybin Dosing Problems by Introducing Biosynthetic Psilocybin to Its Patented Thinstrip Delivery Method

Core One Labs Inc. Announces Board Changes

Core One Labs Inc. (CNSX:COOL) completed the acquisition of Vocan Biotechnologies Inc.

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven